NCT00104468

Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)

An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 50 (planned)
• Sponsor: SGX Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a phase I, single-arm, open-label, multi-center study of rising doses of Troxatyl™ whose purpose is to determine the safety, tolerance, and pharmacokinetics, and to establish the recommended infusion schedule of Troxatyl™.

Conditions

• Acute Myelogenous Leukemia

Interventions

Type	Name	Description
DRUG	Troxatyl™ (Cytotoxic Chemotherapeutic)

Timeline

• Start date: 2003-04-01
• Primary completion: 2007-06-01
• Completion: 2007-06-01
• First posted: 2005-03-01
• Last updated: 2008-01-17

Locations

2 sites across 1 country: United States